Market News
4 min read | Updated on July 15, 2025, 07:26 IST
SUMMARY
HCL Technologies shares will be in focus after it reported a consolidated net profit of ₹3,843 crore for the quarter ended June 2025, marking a decline of 10.8% from ₹3,986 crore in the previous quarter.
HDB Financial Services, HDFC Life, ICICI Prudential Life and ICICI Lombard are among the prominent companies that will report their June quarter earnings today. | Image: Shutterstock
The Indian equity benchmarks are set to open on a flat note on Tuesday, July 15, as indicated by NIFTY futures traded at Gift City in Ahmedabad. NIFTY futures at Gift City also known as Gift NIFTY futures rose 2 points or 0.01% to 25,154.
The Noida-based company’s revenue from operations for the first quarter of the financial year 2025-26 edged up marginally by 0.3% to ₹30,349 crore as compared to ₹30,245 crore quarter-on-quarter (QoQ).
In terms of constant currency (CC), the tech firm’s revenue was down 0.8% QoQ but rose 3.7% year-on-year (YoY).
The company’s revenue from operations also slipped 3.2% quarter-on-quarter (QoQ) to ₹1,244.29 crore in Q1 FY26 in contrast to ₹1,285.65 crore in Q4 FY25.
The firm’s services segment revenue for the quarter under review stood at ₹963.7 crore.
For Q1 FY26, the earnings before interest and taxes (EBIT) fell 17% to ₹168.81 crore as against ₹202.26 crore QoQ. Tata Technologies' margin shrank 13.6% in Q1 FY26 from 15.7% in Q4 FY25.
The company, which supplied 4G gears to state-owned BSNL, had posted a profit of Rs 77.48 crore a year ago.
The consolidated revenue of Tejas Networks plunged about 87 per cent to Rs 202 crore during the reported quarter from Rs 1,563 crore in the June 2024 quarter.
RCPL has partnered with Nepal's conglomerate Chaudhary Group (CG) for the roll out of Campa in the Himalayan country, a joint statement said.
"The launch marks RCPL's entry in Nepal and further reaffirms the company's long-term commitment to the country," it said.
Under the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement.
As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added.
About The Author
Next Story